Literature DB >> 29320902

CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients.

Jatinder K Lamba1, Andrew P Voigt2, Lata Chauhan1, Miyoung Shin1, Richard Aplenc3, Lisa Eidenschink Brodersen2, Alan S Gamis4, Soheil Meshinchi5, Michael R Loken2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29320902      PMCID： PMC7199442          DOI： 10.1080/10428194.2017.1421756

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  12 in total

1.  Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.

Authors:  Michael R Loken; Todd A Alonzo; Laura Pardo; Robert B Gerbing; Susana C Raimondi; Betsy A Hirsch; Phoenix A Ho; Janet Franklin; Todd M Cooper; Alan S Gamis; Soheil Meshinchi
Journal:  Blood       Date:  2012-05-30       Impact factor: 22.113

2.  CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility.

Authors:  Towfique Raj; Katie J Ryan; Joseph M Replogle; Lori B Chibnik; Laura Rosenkrantz; Anna Tang; Katie Rothamel; Barbara E Stranger; David A Bennett; Denis A Evans; Philip L De Jager; Elizabeth M Bradshaw
Journal:  Hum Mol Genet       Date:  2013-12-30       Impact factor: 6.150

Review 3.  Quantitation of hemopoietic cell antigens in flow cytometry.

Authors:  P Poncelet; F George; S Papa; F Lanza
Journal:  Eur J Histochem       Date:  1996       Impact factor: 3.188

4.  CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.

Authors:  Jessica A Pollard; Michael Loken; Robert B Gerbing; Susana C Raimondi; Betsy A Hirsch; Richard Aplenc; Irwin D Bernstein; Alan S Gamis; Todd A Alonzo; Soheil Meshinchi
Journal:  J Clin Oncol       Date:  2016-01-19       Impact factor: 44.544

5.  CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.

Authors:  Jatinder K Lamba; Lata Chauhan; Miyoung Shin; Michael R Loken; Jessica A Pollard; Yi-Cheng Wang; Rhonda E Ries; Richard Aplenc; Betsy A Hirsch; Susana C Raimondi; Roland B Walter; Irwin D Bernstein; Alan S Gamis; Todd A Alonzo; Soheil Meshinchi
Journal:  J Clin Oncol       Date:  2017-06-23       Impact factor: 44.544

6.  Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.

Authors:  Alan S Gamis; Todd A Alonzo; Soheil Meshinchi; Lillian Sung; Robert B Gerbing; Susana C Raimondi; Betsy A Hirsch; Samir B Kahwash; Amy Heerema-McKenney; Laura Winter; Kathleen Glick; Stella M Davies; Patti Byron; Franklin O Smith; Richard Aplenc
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

7.  Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.

Authors:  Leslie Mortland; Todd A Alonzo; Roland B Walter; Robert B Gerbing; Amit K Mitra; Jessica A Pollard; Michael R Loken; Betsy Hirsch; Susana Raimondi; Janet Franklin; Stanley Pounds; Xueyuan Cao; Jeffrey E Rubnitz; Raul C Ribeiro; Alan Gamis; Soheil Meshinchi; Jatinder K Lamba
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

8.  Consistent quantitative gene product expression: #1. Automated identification of regenerating bone marrow cell populations using support vector machines.

Authors:  Andrew P Voigt; Lisa Eidenschink Brodersen; Laura Pardo; Soheil Meshinchi; Michael R Loken
Journal:  Cytometry A       Date:  2016-07-14       Impact factor: 4.355

9.  Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia.

Authors:  Manasi Malik; Joe Chiles; Hualin S Xi; Christopher Medway; James Simpson; Shobha Potluri; Dianna Howard; Ying Liang; Christian M Paumi; Shubhabrata Mukherjee; Paul Crane; Steven Younkin; David W Fardo; Steven Estus
Journal:  Hum Mol Genet       Date:  2015-03-11       Impact factor: 5.121

10.  Consistent quantitative gene product expression: #3. Invariance with age.

Authors:  Michael R Loken; Andrew P Voigt; Lisa Eidenschink Brodersen; Wayne Fritschle; Andrew J Menssen; Denise A Wells
Journal:  Cytometry A       Date:  2016-10-18       Impact factor: 4.355
View more
  4 in total

1.  Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.

Authors:  Mohammed Gbadamosi; Soheil Meshinchi; Jatinder K Lamba
Journal:  Future Oncol       Date:  2018-07-24       Impact factor: 3.404

2.  CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents.

Authors:  Ioannis Papageorgiou; Michael R Loken; Lisa Eidenschink Brodersen; Mohammed Gbadamosi; Geoffrey L Uy; Soheil Meshinchi; Jatinder K Lamba
Journal:  Leuk Lymphoma       Date:  2019-02-05

3.  A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia.

Authors:  Dina Schneider; Ying Xiong; Peirong Hu; Darong Wu; Weizao Chen; Tianlei Ying; Zhongyu Zhu; Dimiter S Dimitrov; Boro Dropulic; Rimas J Orentas
Journal:  Front Oncol       Date:  2018-11-22       Impact factor: 6.244

4.  Diallyl disulfide down-regulates calreticulin and promotes C/EBPα expression in differentiation of human leukaemia cells.

Authors:  Jing Sun; Hongxiang Mu; Jia Yu; Linwei Li; Hongxia Yan; Guoqing Li; Hui Tan; Nanyang Yang; Xiaoyan Yang; Lan Yi
Journal:  J Cell Mol Med       Date:  2018-11-05       Impact factor: 5.310
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.